title: Anti-inflammatory effects of resveratrol occur via inhibition of lipopolysaccharide-induced NF-κB activation in Caco-2 and SW480 human colon cancer cells.
abstract: Resveratrol, a polyphenol abundantly found in grapes and red wine, exhibits beneficial health effects due to its anti-inflammatory properties. In the present study, we evaluated the effect of resveratrol on inflammatory responses induced by lipopolysaccharide (LPS) treatment of human intestinal Caco-2 and SW480 cell lines. In the LPS-treated intestinal cells, resveratrol dose-dependently inhibited the expression of inducible NO synthase (iNOS) mRNA as well as protein expression, resulting in a decreased production of NO. In addition, Toll-like receptor-4 expression was significantly diminished in LPS-stimulated cells after resveratrol pre-treatment. To investigate the mechanisms by which resveratrol reduces NO production and iNOS expression, we examined the activation of inhibitor of κB (IκB) in LPS-stimulated intestinal cells. Results demonstrated that resveratrol inhibited the phosphorylation, as well as the degradation, of the IκB complex. Overall, these results show that resveratrol is able to reduce LPS-induced inflammatory responses by intestinal cells, interfering with the activation of NF-κB-dependent molecular mechanisms.
authors.affiliation: Department of Human Anatomy and Histology, University of Bari, Piazza Giulio Cesare 11, Policlinico, Bari, Italy. ma.panaro@anatomia.uniba.it
authors.forename: Maria Antonietta
authors.initials: MA
authors.lastname: Panaro
authors.forename: Vito
authors.initials: V
authors.lastname: Carofiglio
authors.forename: Angela
authors.initials: A
authors.lastname: Acquafredda
authors.forename: Pasqua
authors.initials: P
authors.lastname: Cavallo
authors.forename: Antonia
authors.initials: A
authors.lastname: Cianciulli
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000378:metabolism* / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000378:metabolism* / Q000627:therapeutic use; D018938:Caco-2 Cells; D045744:Cell Line, Tumor; D002470:Cell Survival; D003110:Colonic Neoplasms / Q000276:immunology / Q000378:metabolism* / Q000473:pathology / Q000517:prevention & control; D019587:Dietary Supplements / Q000009:adverse effects; D015536:Down-Regulation; D020895:Enterocytes / Q000166:cytology / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D020672:I-kappa B Proteins / Q000378:metabolism; D015212:Inflammatory Bowel Diseases / Q000178:diet therapy / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D008070:Lipopolysaccharides; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000235:genetics / Q000378:metabolism; D010766:Phosphorylation; D011499:Protein Processing, Post-Translational; D059748:Proteolysis; D012333:RNA, Messenger / Q000378:metabolism; D000077185:Resveratrol; D013267:Stilbenes / Q000009:adverse effects / Q000378:metabolism* / Q000627:therapeutic use; D051197:Toll-Like Receptor 4 / Q000235:genetics / Q000378:metabolism
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000972:Antineoplastic Agents, Phytogenic; D020672:I-kappa B Proteins; D008070:Lipopolysaccharides; D016328:NF-kappa B; D012333:RNA, Messenger; D013267:Stilbenes; C495345:TLR4 protein, human; D051197:Toll-Like Receptor 4; D009569:Nitric Oxide; C496319:NOS2 protein, human; D052247:Nitric Oxide Synthase Type II; D000077185:Resveratrol